Clinical Therapeutics/Volume 30, Number 8, 2008  Efficacy and Tolerability of Exenatide Monotherapy Over  24 Weeks in Antidiabetic Drug-Naive Patients with Type 2  Diabetes: A Randomized, Double-Blind, Placebo-Controlled,  Parallel-Group Study  ThomasJ. Moretto, MD1; Denfii R. Milton, MS2; Terry D. Ridge, MSN1;  Leigh A. MacConell, PhD3; Ted Okerson, MD3; Anne M. Wolka, PhD2; and  Robert G. Brodows, MD 2  1American Health Network, Indianapolis, Indiana; 2Eli Lilly and Company, Indianapolis, Indiana; and  3Amylin Pharmaceuticals, Inc., San Diego, California  ABSTRACT  Background: Evaluation of exenatide monotherapy  in patients with type 2 diabetes may be of clinical in-  terest based on improvements in glycemic control and  weight that have been reported with the use of exena-  tide in combination with oral antidiabetic agents.  Objective: The aim of this study was to evaluate the  efficacy and tolerability of exenatide monotherapy